Linked Life Data

7729116

Source:http://linkedlifedata.com/resource/pubmed/id/7729116

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1995-5-26
pubmed:abstractText
The use of iron oxide as a superparamagnetic contrast agent for magnetic resonance imaging of the liver has been described previously. When administered intravenously, superparamagnetic iron oxide (SPIO) is sequestered by the reticuloendothelial system causing significant shortening of the T2-relaxation time. The majority of the contrast is taken up by the reticuloendothelial tissue of the liver. Since tumours have reduced or absent reticuloendothelial tissue the effect on relaxation time is minimal and signal intensity differences between tumour and liver are increased. AMI 25 (Laboratoire Guerbet, Paris) is a colloidal solution of ferrous and ferric oxides. We have performed MR examination of the liver in 16 patients with focal liver lesions using AMI 25 as a superparamagnetic contrast agent. Our results indicate that SPIO significantly increases the conspicuity of focal lesions and the effect is greatest in malignant tumours. We observed no adverse reaction to this contrast agent.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0009-9260
pubmed:author
pubmed:issnType
Print
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
215-9
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Superparamagnetic iron oxide imaging of focal liver disease.
pubmed:affiliation
Department of Diagnostic Radiology, University of Manchester.
pubmed:publicationType
Journal Article